Latest news from Double Blind Bio

Our CEO, Shruti Tibrewala, is speaking at CNS Summit on November 4.

Dan Schell, Clinical Leader's chief editor, wrote about six founders building in clinical trials. Our CEO, Shruti, is one of them.

Usage of our product grew quickly this summer. Here is what that taught us about AI agents and adoption in clinical research.

When our AI bill spiked, we looked at where models help, where plain software does the job, and where people should stay in charge.

With fragmented data and no easy way to compare site performance, sponsors often default to familiar choices instead of the best ones.

Clinical trials depend on fast enrollment and reliable site performance. Yet, sponsor-site decisions often fail to reflect these priorities.

GLP-1 drugs are transforming metabolic health, paving the way for a rich pipeline of therapies that push the boundaries of what’s possible.